Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity